Broadband Collaborative Pulse Ablation Instrument Treating Malignant Pulmonary Nodules
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorShanghai Zhongshan Hospital
About this trial
Effectiveness safety and feasibility of the broadband collaborative pulse ablation instrument in treating malignant pulmonary nodules
Eligibility criteria
Qualifiers
Age: between 18 and 70 years old with no gender limitation;
Malignant pulmonary nodules diagnosed by cytology and/or histopathology, or the number of tumors ≤3. The pulmonary nodules were oligometastatic and the primary lesions were stable, with no uncontrolled metastasis to other sites;
Surgery is not available or the patient refuses surgical treatment;
Nodules' Maximum diameter≤2cm;
Disqualifiers
An electronic device is implanted near the target area or an implanted pacemaker or defibrillator is present in the body;
Coagulation dysfunction with severe bleeding tendency and short-term correction (prothrombin time >18s, prothrombin activity <40%, platelet <80×109 /L);
Patient who can not stop taking Antiplatelet and anticoagulant drugs 5 days before surgery;
Severe pulmonary fibrosis and pulmonary hypertension;
Trial design
Treatments tested in this trial
- broadband collaborative pulse ablation
Treatment groups
3 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov